Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Zeitschrift für Gerontologie und Geriatrie 4/2019

03.06.2019 | Themenschwerpunkt

Diagnosis and treatment of cognitive impairment

verfasst von: MD Prof. Christine A. F. von Arnim, Thorsten Bartsch, Andreas H. Jacobs, Jill Holbrook, Philipp Bergmann, Tania Zieschang, M. Cristina Polidori, Richard Dodel

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

As a result of the aging population dementia is a growing challenge, especially in healthcare. Nevertheless, cognitive disorders are often not systematically evaluated, especially during hospital stays for other reasons; however, cognitive impairment is associated with a number of geriatric syndromes, including falls, delirium, dysphagia and lack of adherence to treatment plans. This article considers the current state of diagnosis and treatment of dementia. Non-pharmacological therapeutic approaches as well as current and future pharmacological treatment options are discussed. The drugs of choice for the symptomatic treatment of cognitive deficits in Alzheimer’s disease and Parkinson-associated dementia are cholinesterase inhibitors and memantine; there is no specific pharmacological treatment for other types of dementia. Prevention and treatment of cardiovascular risk factors can potentially retard the progression of possibly all forms of dementia.
Literatur
1.
Zurück zum Zitat Albert MS, Dekosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia 7:270–279 CrossRefPubMed Albert MS, Dekosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia 7:270–279 CrossRefPubMed
4.
Zurück zum Zitat Bond J, Stave C, Sganga A et al (2005) Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey. Int J Clin Pract Suppl 146:8–14 CrossRef Bond J, Stave C, Sganga A et al (2005) Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey. Int J Clin Pract Suppl 146:8–14 CrossRef
5.
Zurück zum Zitat Braak H, Thal DR, Ghebremedhin E et al (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960–969 CrossRefPubMed Braak H, Thal DR, Ghebremedhin E et al (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960–969 CrossRefPubMed
6.
Zurück zum Zitat Bruun M, Rhodius-Meester HFM, Koikkalainen J et al (2018) Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimers Dement (amst) 10:509–518 Bruun M, Rhodius-Meester HFM, Koikkalainen J et al (2018) Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimers Dement (amst) 10:509–518
7.
Zurück zum Zitat Buter K, Motzek T, Dietz B et al (2017) Dementia-friendly hospital wards : expert recommendations for planning and design. Z Gerontol Geriatr 50:67–72 CrossRefPubMed Buter K, Motzek T, Dietz B et al (2017) Dementia-friendly hospital wards : expert recommendations for planning and design. Z Gerontol Geriatr 50:67–72 CrossRefPubMed
8.
Zurück zum Zitat Cummings JL (1997) The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Baillieres Clin Neurol 48:10–16 Cummings JL (1997) The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Baillieres Clin Neurol 48:10–16
9.
Zurück zum Zitat Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13:614–629 CrossRefPubMed Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13:614–629 CrossRefPubMed
10.
Zurück zum Zitat Ehrensperger MM, Berres M, Taylor KI et al (2010) Early detection of Alzheimer’s disease with a total score of the German CERAD. J Int Neuropsychol Soc 16:910–920 CrossRefPubMed Ehrensperger MM, Berres M, Taylor KI et al (2010) Early detection of Alzheimer’s disease with a total score of the German CERAD. J Int Neuropsychol Soc 16:910–920 CrossRefPubMed
11.
Zurück zum Zitat Gillette-Guyonnet S, Andrieu S, Nourhashemi F et al (2011) Long-term progression of Alzheimer’s disease in patients under antidementia drugs. Alzheimer’s Dementia 7:579–592 CrossRefPubMed Gillette-Guyonnet S, Andrieu S, Nourhashemi F et al (2011) Long-term progression of Alzheimer’s disease in patients under antidementia drugs. Alzheimer’s Dementia 7:579–592 CrossRefPubMed
12.
Zurück zum Zitat Harper L, Barkhof F, Fox NC et al (2015) Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. J Neurol Neurosurg Psychiatr 86:1225–1233 CrossRef Harper L, Barkhof F, Fox NC et al (2015) Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. J Neurol Neurosurg Psychiatr 86:1225–1233 CrossRef
13.
Zurück zum Zitat Jack CR Jr., Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of alzheimer’s disease. Alzheimer’s Dementia 14:535–562 CrossRefPubMed Jack CR Jr., Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of alzheimer’s disease. Alzheimer’s Dementia 14:535–562 CrossRefPubMed
15.
Zurück zum Zitat Kawas CH, Kim RC, Sonnen JA et al (2015) Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study. Baillieres Clin Neurol 85:535–542 Kawas CH, Kim RC, Sonnen JA et al (2015) Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study. Baillieres Clin Neurol 85:535–542
16.
Zurück zum Zitat Khanna MR, Kovalevich J, Lee VM et al (2016) Therapeutic strategies for the treatment of tauopathies: hopes and challenges. Alzheimer’s Dementia 12:1051–1065 CrossRefPubMed Khanna MR, Kovalevich J, Lee VM et al (2016) Therapeutic strategies for the treatment of tauopathies: hopes and challenges. Alzheimer’s Dementia 12:1051–1065 CrossRefPubMed
17.
Zurück zum Zitat Legdeur N, Badissi M, Carter SF et al (2018) Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatr 18:289 CrossRefPubMedPubMedCentral Legdeur N, Badissi M, Carter SF et al (2018) Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatr 18:289 CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Livingston G, Sommerlad A, Orgeta V et al (2017) Dementia prevention, intervention, and care. Lancet 390:2673–2734 CrossRefPubMed Livingston G, Sommerlad A, Orgeta V et al (2017) Dementia prevention, intervention, and care. Lancet 390:2673–2734 CrossRefPubMed
19.
Zurück zum Zitat Mckeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Baillieres Clin Neurol 89:88–100 Mckeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Baillieres Clin Neurol 89:88–100
20.
Zurück zum Zitat Mckhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Baillieres Clin Neurol 34:939–944 Mckhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Baillieres Clin Neurol 34:939–944
21.
Zurück zum Zitat Mckhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia 7:263–269 CrossRefPubMed Mckhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia 7:263–269 CrossRefPubMed
22.
Zurück zum Zitat Nasreddine ZS, Phillips NA, Bedirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699 CrossRefPubMed Nasreddine ZS, Phillips NA, Bedirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699 CrossRefPubMed
23.
Zurück zum Zitat Otto M, Lewczuk P, Wiltfang J (2008) Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods 44:289–298 CrossRefPubMed Otto M, Lewczuk P, Wiltfang J (2008) Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods 44:289–298 CrossRefPubMed
24.
25.
Zurück zum Zitat Polidori MC, Menculini G, Senin U et al (2001) Dementia, depression and parkinsonism: a frequent association in the elderly. J Alzheimer’s Dis 3:553–562 CrossRef Polidori MC, Menculini G, Senin U et al (2001) Dementia, depression and parkinsonism: a frequent association in the elderly. J Alzheimer’s Dis 3:553–562 CrossRef
26.
Zurück zum Zitat Rinne JO, Brooks DJ, Rossor MN et al (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363–372 CrossRefPubMed Rinne JO, Brooks DJ, Rossor MN et al (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363–372 CrossRefPubMed
27.
28.
Zurück zum Zitat Rountree SD, Atri A, Lopez OL et al (2013) Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimer’s Dementia 9:338–345 CrossRefPubMed Rountree SD, Atri A, Lopez OL et al (2013) Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimer’s Dementia 9:338–345 CrossRefPubMed
29.
Zurück zum Zitat Salloway S, Sperling R, Brashear HR (2014) Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease. N Engl J Med 370:1460 CrossRefPubMed Salloway S, Sperling R, Brashear HR (2014) Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease. N Engl J Med 370:1460 CrossRefPubMed
30.
Zurück zum Zitat Sevigny J, Chiao P, Bussiere T et al (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature 537:50–56 CrossRefPubMed Sevigny J, Chiao P, Bussiere T et al (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature 537:50–56 CrossRefPubMed
31.
Zurück zum Zitat Stock S, Ihle P, Simic D et al (2018) Prevalence of dementia of insured persons with and without German citizenship : a study based on statuatory health insurance data. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 61:404–411 CrossRefPubMed Stock S, Ihle P, Simic D et al (2018) Prevalence of dementia of insured persons with and without German citizenship : a study based on statuatory health insurance data. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 61:404–411 CrossRefPubMed
32.
Zurück zum Zitat Ten Kate M, Ingala S, Schwarz AJ et al (2018) Secondary prevention of Alzheimer’s dementia: neuroimaging contributions. Alzheimer’s Res Ther 10:112 CrossRef Ten Kate M, Ingala S, Schwarz AJ et al (2018) Secondary prevention of Alzheimer’s dementia: neuroimaging contributions. Alzheimer’s Res Ther 10:112 CrossRef
33.
Zurück zum Zitat Ten Kate M, Redolfi A, Peira E et al (2018) MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer’s Res Ther 10:100 CrossRef Ten Kate M, Redolfi A, Peira E et al (2018) MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer’s Res Ther 10:100 CrossRef
34.
Zurück zum Zitat Thal DR, Von Arnim C, Griffin WS et al (2013) Pathology of clinical and preclinical Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 263(Suppl 2):137–145 CrossRef Thal DR, Von Arnim C, Griffin WS et al (2013) Pathology of clinical and preclinical Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 263(Suppl 2):137–145 CrossRef
35.
Zurück zum Zitat Wardlaw JM, Valdes Hernandez MC, Munoz-Maniega S (2015) What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc 4:1140 CrossRefPubMed Wardlaw JM, Valdes Hernandez MC, Munoz-Maniega S (2015) What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc 4:1140 CrossRefPubMed
36.
Zurück zum Zitat Whitwell JL, Przybelski SA, Weigand SD et al (2007) 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer’s disease. Brain 130:1777–1786 CrossRefPubMed Whitwell JL, Przybelski SA, Weigand SD et al (2007) 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer’s disease. Brain 130:1777–1786 CrossRefPubMed
Metadaten
Titel
Diagnosis and treatment of cognitive impairment
verfasst von
MD Prof. Christine A. F. von Arnim
Thorsten Bartsch
Andreas H. Jacobs
Jill Holbrook
Philipp Bergmann
Tania Zieschang
M. Cristina Polidori
Richard Dodel
Publikationsdatum
03.06.2019
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 4/2019
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-019-01560-0